首页 > 市场调查报告书 > 製药

基因治疗学和RNAi 基因疗法

癌症基因治疗市场规模、份额和成长分析（按类型、治疗方法、产品类型、最终用途和地区划分）—2026-2033年产业预测

市场调查报告书

商品编码

1900427

癌症基因治疗市场规模、份额和成长分析（按类型、治疗方法、产品类型、最终用途和地区划分）—2026-2033年产业预测

Cancer Gene Therapy Market Size, Share, and Growth Analysis, By Type (Ex-Vivo, In-Vivo), By Therapy (Oncolytic Virotherapy, Gene-Induced Immunotherapy), By Product, By End Use, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月16日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球癌症基因治疗市场规模预计在 2024 年达到 42.5 亿美元，从 2025 年的 51.6 亿美元增长到 2033 年的 243.4 亿美元，在预测期（2026-2033 年）内复合年增长率为 21.4%。

全球癌症发生率的快速成长是推动癌症基因治疗市场成长的主要因素。对创新癌症治疗方法的需求不断增长，加上基因工程技术的进步和对新型治疗方法的巨额投资，预计将显着提振市场需求。基因技术的持续进步及其在肿瘤学应用研究的活性化，正激励企业开发突破性的癌症基因疗法。此外，人们越来越倾向于选择旨在提高存活率的个人化癌症治疗方案，加上政府对癌症患者的资助，预计将为该领域的参与者带来新的机会。然而，高昂的治疗成本、潜在的副作用以及复杂的生产製造等挑战，可能会阻碍癌症基因治疗市场的长期发展。

全球癌症基因治疗市场驱动因素

全球癌症基因治疗市场正经历显着成长，这主要得益于基因工程和基因组定序技术的进步，而这些技术的进步又得益于对基因研究倡议的大量投资。这些基因领域的创新进展正日益融入癌症研究，进而催生出突破性的癌症基因疗法。这种融合不仅提高了癌症治疗的有效性，也拓宽了患者的治疗选择，最终推动了市场的发展。随着研究的不断深入，新型和改良型基因疗法在对抗癌症方面的潜力预计将持续光明。

限制全球癌症基因治疗市场的因素

全球癌症基因治疗市场面临的主要挑战之一是这些先进疗法的高成本，导致许多患者无法获得治疗。相关技术的复杂性以及研发所需的大量投资是造成高成本的主要原因。因此，经济障碍限制了癌症基因疗法的广泛应用，并非所有患者都能获得这些创新疗法。这个经济问题阻碍了基因疗法融入标准癌症治疗体系的进程，最终影响了整个产业有效治疗方案的成长和普及。

全球癌症基因治疗市场趋势

全球癌症基因治疗市场正经历一个显着趋势：对联合治疗的需求日益增长，这主要源于越来越多的癌症患者寻求先进治疗方法以提高存活率。为了因应这一转变，基因治疗供应商正不断创新，开发新的联合治疗，探索不同治疗方法的协同效应，从而扩大市场份额并改善患者预后。随着医疗专业人员越来越重视个人化医疗和客製化治疗通讯协定，癌症基因治疗领域对联合治疗的关注为企业创造了巨大的成长机会，使其在不断发展的肿瘤学领域中处于领先地位。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Novartis AG（Switzerland）
Gilead Sciences, Inc.（USA）
Bristol Myers Squibb Company（USA）
CRISPR Therapeutics（Switzerland）
Amgen Inc.（USA）
Merck KGaA（Germany）
Intellia Therapeutics, Inc.（USA）
Adaptimmune Therapeutics（UK）
Autolus Therapeutics（UK）
Sangamo Therapeutics, Inc.（USA）
Vertex Pharmaceuticals（USA）
Abeona Therapeutics Inc.（USA）
Johnson & Johnson（USA）
Pfizer Inc.（USA）
AstraZeneca（UK）
Takeda Pharmaceutical Company Limited（Japan）

结论与建议

简介目录

Product Code: SQMIG35G2180

Global Cancer Gene Therapy Market size was valued at USD 4.25 Billion in 2024 and is poised to grow from USD 5.16 Billion in 2025 to USD 24.34 Billion by 2033, growing at a CAGR of 21.4% during the forecast period (2026-2033).

The surge in global cancer incidence is a primary catalyst for the growth of the cancer gene therapy market. The increasing demand for innovative cancer treatments, coupled with advancements in genetic engineering and substantial investments in new therapies, is expected to significantly boost market demand. Ongoing progress in gene technologies and heightened research into their oncology applications are encouraging companies to create groundbreaking cancer gene therapies. Furthermore, the rising preference for personalized cancer treatments aimed at improving survival rates, along with supportive government funding for cancer patients, is anticipated to open up new opportunities for providers in this sector. However, challenges such as high treatment costs, potential adverse reactions, and manufacturing complexities could hinder the long-term development of the cancer gene therapy market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Gene Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Gene Therapy Market Segments Analysis

Global Cancer Gene Therapy Market is segmented by Type, Therapy, Product, End Use and region. Based on Type, the market is segmented into Ex-Vivo and In-Vivo. Based on Therapy, the market is segmented into Oncolytic Virotherapy, Gene-Induced Immunotherapy and Gene Transfer. Based on Product, the market is segmented into Viral Vectors, Non-Viral Vectors and Other Products. Based on End Use, the market is segmented into Biopharma Companies, Research Institutes and Other End-Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Gene Therapy Market

The Global Cancer Gene Therapy market is experiencing significant growth, largely fueled by advancements in genetic engineering and genome mapping technologies, which have benefited from substantial investments in gene research initiatives. These innovative developments in genetics are increasingly being incorporated into oncology research, leading to the creation of groundbreaking cancer gene therapies. This integration not only enhances the effectiveness of cancer treatments but also broadens the therapeutic options available to patients, ultimately propelling the market forward. As research continues to evolve, the potential for new and improved gene therapies in the fight against cancer remains promising.

Restraints in the Global Cancer Gene Therapy Market

One significant challenge facing the Global Cancer Gene Therapy market is the high cost associated with these advanced treatments, which often makes them inaccessible for many patients. The intricacy of the technology involved and the considerable investment required for development contribute to these elevated expenses. Consequently, the financial barrier limits the widespread adoption of cancer gene therapy, as not all patients can afford these innovative options. This affordability issue hampers the progress of integrating gene therapy into standard cancer care, ultimately affecting the overall growth and accessibility of effective treatment alternatives within the industry.

Market Trends of the Global Cancer Gene Therapy Market

The Global Cancer Gene Therapy market is witnessing a notable trend toward the increasing demand for combination therapies, driven by a rising prevalence of cancer patients seeking enhanced treatment options to improve survival rates. This shift is prompting gene therapy providers to innovate and develop new combination therapies that synergize the efficacy of various treatment modalities, thereby expanding their market presence and enhancing patient outcomes. As healthcare professionals emphasize personalized medicine and tailored treatment protocols, the focus on combination therapies in cancer gene therapy creates substantial growth opportunities for companies, positioning them at the forefront of the evolving oncology landscape.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Cancer Gene Therapy Market Size by Type & CAGR (2026-2033)

Market Overview
Ex-Vivo
In-Vivo

Global Cancer Gene Therapy Market Size by Therapy & CAGR (2026-2033)

Market Overview
Oncolytic Virotherapy
Gene-Induced Immunotherapy
Gene Transfer

Global Cancer Gene Therapy Market Size by Product & CAGR (2026-2033)

Market Overview
Viral Vectors
- Adenoviruses
- Lentiviruses
- Retrovirus
- Adeno Associated Virus
- Herpes Simplex Virus
- Vaccinia Virus
- Other Viral Vectors
Non-Viral Vectors
Other Products

Global Cancer Gene Therapy Market Size by End Use & CAGR (2026-2033)

Market Overview
Biopharma Companies
Research Institutes
Other End-Users

Global Cancer Gene Therapy Market Size & CAGR (2026-2033)

North America (Type, Therapy, Product, End Use)
- US
- Canada
Europe (Type, Therapy, Product, End Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Therapy, Product, End Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Therapy, Product, End Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Therapy, Product, End Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CRISPR Therapeutics (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Intellia Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adaptimmune Therapeutics (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Autolus Therapeutics (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sangamo Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abeona Therapeutics Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments